Hormone and cytokine circadian alteration in non-small cell lung cancer patients

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 3, 2012, Pages 691-702

  Mazzoccoli, G ^a   Sothern, R B ^b   Francavilla, M ^a   Giuliani, F ^a   Carughi, S ^a   Muscarella, L A ^a   Fazio, V M ^a   Parrella, P ^a   Vinciguerra, M ^c   Tarquini, R ^d  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cortisol; GH; IGF1 IL2; Melatonin; Rhythm

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; INTERLEUKIN 2; MELATONIN; SOMATOMEDIN C;

ADULT; ARTICLE; CANCER STAGING; CIRCADIAN RHYTHM; CONTROLLED STUDY; GROWTH HORMONE BLOOD LEVEL; HUMAN; LIGHT DARK CYCLE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREND STUDY;

EID: 84868029449     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500315     Document Type: Article

References (34)

1. Rudd MF, Webb EL, Matakidou A, and the GELCAPS Consortium. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006; 16:693-701. (Pubitemid 43830689)
2. Perry JK, Emerald BS, Mertani HC, et al. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006; 16:277-89. (Pubitemid 44793716)
3. Kleinberg DL, Wood TL, Fürth PA, et al. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocrine Rev 2009; 30: 51-74.
4. Gennigens C, Menetrier-Caux C, Droz JP. Insulinlike growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58: 124-45.
5. Roddam AW, Allen NE, Appleby P, et al. Insulinlike growth factors, their binding proteins, and prostate cancer risk: analysis of Individual patient data from 12 prospective studies. Ann Intern Med 2008; 149( 7): 461-71.
6. Rinaldi S, Cleveland R, Norat T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk:results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010; 126: 1702-15.
7. Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009; 124: 2416-29.
8. Donovan EA, Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 2008; 66:91-98. (Pubitemid 351446110)
9. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003; 4:649-61. (Pubitemid 37280160)
10. Schemhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I. Rotating night shins and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001; 93:1563-68. (Pubitemid 32998486)
11. Filipski E, Subramanian P, Carrière J, Guettier C, Barbason H, Levi F. Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res 2009; 680: 95-105.
12. Guess J. Circadian disruption factors and inflammation. J Interferon Cytokine Res 2009; 29: 249-54.
13. Nelson W, Tong YL, Lee YK, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6: 30523.
14. Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. J Biol Rhythms 2007; 22: 291-8.
15. Filipski E, King VM, Li XM, Granda TG, Mormont MC, Liu X. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002; 94: 6907.
16. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nature Rev Cancer 2003; 3: 35061.
17. Mazzoccoli G, Correra M, Bianco G, et al. Age-related changes of neuro-endocrine-immune interactions in healthy humans. J Biol Regul Homeost Agents 1997; 11:143-7. (Pubitemid 28161873)
18. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol 2006; 64: 115-21.
19. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia Nature Rev Cancer 2008; 8: 915-28.
20. Waters MJ, Conway-Campbell BL. The oncogenicpotential of autocrine human growth hormone in breast cancer. PNAS 2004; 101: 14992-93.
21. DeGraff DJ, Aguiar AA, Sikes RA. Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 2009; 1: 115-30.
22. Ryan PD, Goss PE. The emerging role of the insulinlike growth factor pathway as a therapeutic target in cancer. The Oncologist 2008; 13:16-24. (Pubitemid 351206693)
23. Sachdev D, Zhang X, Matise I, et al. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 2009; 1: 1-12.
24. Braconi C, Bracci R, Bearzi I, et al. Insulin-like growth factor (IGF) land 2 help to predict disease outcome in GIST patients. Annals Oncol 2008; 19:1293-98. (Pubitemid 351911960)
25. Gong Y, Yao E, Shen R, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R 1507). PLoS One 2009; 4: e7273.
26. Anzo M, Cobb LJ, Hwang DL, et al. Targeted deletion of hepatic Igfl in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 2008; 68: 3342-9.
27. Vinciguerra M, Santini MP, Claycomb WC, Ladurner AG, Rosenthal N. Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via Sir TI activity. Aging (Albany NY) 2009; 2: 43-62.
28. Mazzoccoli G, Giuliani A, Bianco G, et al. Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: temporal relationship with growth hormone (GH) levels. Anticancer Res 1999; 19:1397-9. (Pubitemid 29257465)
29. Oscarsson J, Johansson G, Johansson J-O, et al. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults. Clin Endocrinol 1997; 46:63-68. (Pubitemid 27072847)
30. Mazzoccoli G, Grilli M, Carughi S, et al. Immune system alterations in lung cancer patients. Int J Immunopathol Pharmacol 2003; 16:167-74. (Pubitemid 36850857)
31. Felaco P, Castellani ML, De Lutiis MA, et al. IL-32: a newly-discovered proinflammatory cytokine. J Biol Regul Homeost Agents 2009; 23: 141-7.
32. Ilonidis G, Parapanisiou E, Anogeianaki A, et al. Interleukin -1beta (IL-1 beta), interleukin 6 (I L6) and tumor necrosis factor (TNF) in plasma and pleural fluid of pneumonia, lung cancer and tuberculous pleuritis. J Biol Regul Homeost Agents 2006; 20: 41-46.
33. Lissoni P, Brivio F, Rovelli F, et al. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents 2000; 14:275-77. (Pubitemid 32124116)
34. Gusenoff JA, Harman S, Veldhuis JD, et al. Cortisol and GH secretory dynamics, and their interrelationships, in healthy aged women and men Am J Physiol Endocrinol Metab 2001; 280: E616-E625